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by size-exclusion chromatography
1,*

1

1

2

Ali NAZARI SHIRVAN , Maedeh SAMIANIFARD , Naser GHODSIAN
Department of Proteomics and Biochemistry, Razi Vaccine and Serum Research Institute, Karaj, Iran
2
Department of Viral Quality Control, Razi Vaccine and Serum Research Institute, Karaj, Iran

Received: 02.06.2015

Accepted/Published Online: 12.11.2015

Final Version: 05.01.2016

Abstract: Avian influenza viruses represent a rising threat of pandemic influenza. Allantoic fluid including influenza virus H9N2 was
run on downstream processing to purify the virus. To do this, allantoic fluid was clarified and concentrated. It was applied to size
exclusion chromatography. Different parameters such as ovalbumin, protein content, and hemagglutinin activity were determined to
confirm the purity. The results may suggest that this method is quite efficient for achieving a purified H9N2 influenza virus and further
reveal that size-exclusion chromatography is a practical method for purifying avian influenza viruses. In conclusion, this procedure can
be used in vaccine production and antiserum preparation as an alternative to traditional methods and also can be considered in the
purifying of other viruses when there is no facility of ultracentrifuge or zonal centrifuge.
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1. Introduction
Avian influenza (AI) refers to flu caused by type A strains
of the influenza virus that is an infectious disease of
birds. Influenza viruses are classified into three types:
A, B, and C. Only influenza A viruses infects birds. The
avian influenza virus (AIV) is a member of the family
Orthomyxoviridae, containing negative-sense and singlestranded RNA (1). Based on their pathogenicity, two
types of AIV have been described: the highly pathogenic
type (HPAIV), which causes severe disease with high
mortality, and the low pathogenic type (LPAIV), inducing
asymptomatic or mild infection (2).
According to the main surface proteins, hemagglutinin
(HA) and neuraminidase (NA), influenza A viruses are
categorized into different subtypes: 17 for HA and 10 for
NA. The HA of the influenza virus is the major surface
protein inducing protective immune responses (3).
According to the World Health Organization (WHO), all
H9 viruses found in wild birds and poultry are LPAIVs.
During 1994–1999, infections in poultry that were
caused by influenza viruses of the H9 subtype were
noticeably prevalent. Outbreaks of the H9N2 subtype
occurred in domestic ducks, chickens, and turkeys in
Europe and the United States (4). This type of bird flu was
reported in 1998 on a broiler chicken farm in Tehran, Iran,
and from neighboring provinces (5,6). Vaccines have an
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important role in controlling and protecting the poultry
industry from infectious diseases. Influenza vaccines
are usually prepared from a mix of an adjuvant and
harvested allantoic fluid. The resulting product includes
a high amount of unwanted impurities of allantoic fluid
such as ovalbumin. For this reason, applying purification
procedures in vaccine production is important.
Generally, viruses have been purified by a variety
of methods, including PEG/NaCl precipitation (7),
ultracentrifugation (8), column chromatography (9),
high-performance liquid chromatography (10), and
centrifugation on a sucrose gradient, which are mostly
used on the laboratory scale. In 1977, centrifugation on
a sucrose gradient was carried out for avian influenza
purification (11). Chromatography has been suggested
as a novel method in virus purification (9). Here we
describe a standard strategy for the purification of avian
influenza virus using centrifugation, ultrafiltration, and
chromatography techniques.
In this study, we report a simple and effective procedure
for concentrating and purifying the avian influenza H9N2
virus with size-exclusion chromatography. Our goal was
to set up a platform for purification of the virus that can
be applied from small to large scale in vaccine production
and antiserum preparation instead of other techniques
such as zonal centrifugation.
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2. Materials and methods
2.1. Egg incubation and antigen preparation
Avian influenza virus strain A/chicken/Iran/259/1998
(H9N2), confirmed by the Central Veterinary Laboratory
of Webridge, Surrey, UK, was propagated in 10-day-old
specific pathogen-free embryonated chicken eggs (12).
After incubation for 48 h at 37 °C, the infectious allantoic
fluid was harvested and pooled. The fresh allantoic fluid
was clarified and host debris was separated from it by
centrifuging at 4500 rpm for 60 min at 4 °C, and then the
clarified fluid was checked for its HA titer (13). Clarified
fluid was inactivated by formalin at 1/2000 for 2 days at
37 °C. Three batches of each active and inactive virus
were used in the next steps of this work in three different
conditions.
2.2. Ultrafiltration of the virus
After clarifying active and inactive antigens, they were
concentrated 10-, 20-, and 35-fold using cross-flow
ultrafiltration through a 100-kDa cutoff cassette (Slice 200,
Sartorius, Germany) at room temperature. The permeated
and concentrated samples were gathered in intervals to
determine the HA activity. The concentration process was
repeated twice for each batch. Phosphate-buffered saline
(PBS), 10 mM, and 50 mM NaCl, pH 7.5, were used in all
steps for washing and diafiltration. All of the concentrated
samples were kept at –70 °C for future experiments.
2.3. Purification of the virus
Size-exclusion chromatography of concentrated samples
containing both active and inactive influenza virion was
performed separately using Sephadex G-75 and G-100
and Sepharose CL-4B (GE Healthcare) resins in PBS at
room temperature. Each sample (10-, 20-, and 35-fold
concentrated allantoic fluid) was loaded on a column of
100 cm × 2.5 cm, which was packed with the above resins
and equilibrated with the same buffer. To separate the
virus, different amounts of concentrated sample (2%–10%
of the total bed volume) were loaded into the column and
washed at a flow rate of 0.5–1 mL/min. All fractions were
collected and analyzed for their absorbance at 260 nm and
280 nm using a UV/VIS spectrophotometer (Pharmacia
Biotech, Ultraspect 2000), and for HA activity, ovalbumin,
and protein concentration (Bradford assay (14), Bio-Rad
kit, USA).
2.4. HA titer test
HA assay was performed to assess the viral titration in
all steps. To do this, 50 µL of PBS was added to a roundbottomed 96-well plate (Nunc, Pasadena, TX, USA) and
an equivalent volume of virus sample was added to the
first rows and mixed well. Then 50 µL of the previous
suspension was transferred to the next following well.
Twofold serial dilutions of 50 µL of virus suspension were
made across the plate. A volume of 1% chicken’s red blood
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cells was added to dilute virus suspensions. The microplate
was kept at room temperature for 30 min. The red blood
cells that were not bound by influenza virus sunk to the
bottom of the well, defining the HA activity (13).
2.5. Protein assay
Protein concentration was determined by quick-start
Bradford protein assay (Bio-Rad). The standard curve
was prepared using a range of dilutions of bovine serum
albumin according to instructions of the manufacturer. All
samples were measured in duplicate.
2.6. SDS-PAGE
Proteins in the processed fractions were visualized using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) based on the Laemmli method (15). The
purified viral samples from active and inactive batches were
separated on 12% polyacrylamide gel. Gel electrophoresis
(SDS-PAGE) was carried out using the Mini-PROTEAN
Bio-Rad system. Polypeptide bonds were revealed by
staining the gel with silver nitrate.
2.7. Ovalbumin ELISA test
Indirect enzyme-linked immunosorbent assay (ELISA)
was used to detect ovalbumin in allantoic fluid and purified
samples. The test was carried out based on the supplier’s
protocol (Seramun Diagnostica GmbH, Heidesee,
Germany) for different dilutions.
3. Results
3.1. Harvesting and concentrations
A total of 6 batches of inactive and active allantoic fluid
including H9N2 virus were produced and clarified and
checked for their HA activity. HA activity was determined
in all concentrated samples, including influenza viruses.
These samples revealed no loss of HA activity before and
after this step. The results from the HA test of influents
and effluents of each sample showed no virus penetration
during cross-flow filtration, while the HA activity in
concentrated samples was correlated with the fold of
concentration in both active and inactive viruses (Table).
HA activity in both active and inactive concentrated
samples showed a constant stability based on this test after
more than 6 months at 4 °C.
3.2. Purification
In this study two forms of viruses were applied in a varied
range of gel filtration resins to find out the efficiency of
column chromatography in virus purification. In general,
all columns were run with the same buffer and same
conductivity, whereas the volume of the loaded sample
and the flow rate were variable. Neither Sephadex G-75
nor G-100 acted as a useful resin for separation of the
influenza virus from other allantoic fluid proteins (data
not shown). However, the Sepharose CL-4B column was
capable of separating the influenza H9N2 virus from
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Table. Specification of viral samples through the purification procedure.
Protein,
mg/mL

Ovalbumin,
µg/mL

Active H9N2 virus
(concentrated) b

15

16

82

Purified active
H9N2 virus

13

0.66

0.13

Inactive H9N2 virus
(concentrated) b

13

18

68

Purified inactive
H9N2 virus

12

0.4

0.07

HA titer in all permeated samples was zero.
The concentration factor for this sample was equal to 20.

other proteins of the allantoic fluid. The volume of the
loaded sample from different folds of concentrations in
both active and inactive forms was used to optimize the
column’s parameters. Comparing all acquired data showed
the best virus purification with a flow rate of 40–60 mL/h
and sample volume of up to a maximum of 10% of the
total bed volume. Figure 1 illustrates the behavior of the
Sepharose CL-4B column loaded with 2% of the void
volume with the active H9N2 virus. Comparing HA
activity along with absorbance of fractions at 260 and
280 nm showed complete separation of viral particles
in the first peak. In the next step, the Sepharose CL-4B
column was loaded with 10% of the void volume with the
inactivated H9N2 virus. Based on this chromatogram,
only the eluted fractions from the first peak showed HA
activity (Figure 2).
The amount of ovalbumin as the main impurity in
allantoic fluid was determined by ELISA assay to find
out the purity of the virus. The contents of ovalbumin in
concentrated and permeated samples were over the range
of kit limitations, while in pure samples it was less than
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Figure 1. Chromatography of active concentrate of H9N2
virus on Sepharose CL-4B loaded with 2% of bed volume. UV
absorbance at 280 nm (blue line), UV absorbance at 260 nm (red
line), and HA activity (green line) are illustrated.
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Figure 2. Chromatography of inactive concentrate of H9N2
virus on Sepharose CL-4B loaded with 10% of bed volume. UV
absorbance at 280 nm (blue line), UV absorbance at 260 nm (red
line), and HA activity (green line) are illustrated.

0.2 µg/mL, within the range of WHO limitations for eggbased human influenza vaccine (Table).
SDS-PAGE analysis of purified active and inactive
samples showed that the purified virus was in agreement
with the findings of a previous study (16). Although the
same concentrations were used for both active and inactive
samples, the bands in the inactive sample were observed
with lower intensity, probably because of having formalin
(Figure 3).
4. Discussion
The crucial role of influenza virus in veterinary and
human fields forced researchers and industries to prepare
the whole virus particle through different purifying
methods. For instance, influenza virus has been separated
on a sucrose gradient in the laboratory and on a large scale
(11,17). Downstream processing in vaccine production
has a great role and is a crucial step. Most of the efforts
in virus purification recently moved towards column
chromatography, such as size-exclusion chromatography
(18), which might be exploited as the final step.
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Figure 3. SDS-PAGE of purified sample. Lane 1, protein marker;
lane 2, harvested allantoic fluid; lane 3, active AIV purified from
first batch; lane 4, active AIV purified from 4th batch; lane 5,
inactive AIV purified from first batch; lane 6, inactive AIV
purified from 4th batch.

Clarified egg-derived avian influenza H9N2 was
concentrated through tangential cross-flow filtration using
a 100-kDa cassette a maximum of 30 times that was fed
with active and inactivated virus. A similar method was
reported using cell-derived human influenza virus with
high recovery of HA activity, as resulted in this work
(9). This step was carried out for different volumes of
samples from 1 to 10 L. In all conditions, the permeated
samples did not show any detectable HA activity (Table),
while HA activity was increased in the concentrated part.
By increasing the concentration factor and volume of

samples, data showed that the filtration step of this method
is effective to use in large-scale concentration of the virus
with high HA activity before column chromatography.
The avian H9N2 subtype was purified at laboratory
scale after separation by a sucrose gradient at a sufficient
amount to use in laboratory analysis tests (13). Compared
to that, here we set up column chromatography for largescale purification of avian influenza. Among the resins that
were used in this study, Sepharose Cl-4B showed the best
separation. This column was able to separate whole intact
viral particles from ovalbumin as the major protein of the
allantoic fluid in the first peak. As shown in Figures 1 and 2
for both active and inactive forms of sample, the behavior
of separation is nearly identical, with complete separation
of ovalbumin. In addition, because of the large size of
influenza virions, the mass transfer effects may enhance
tailing of the elution peak (Figure 1). Compared to other
studies on different viruses such as turkey coronavirus
(19) and equine influenza (20), whole virus particles were
recovered in the void volume.
This study presented a straightforward downstream
process that can be carried out in the purification of active
and inactive avian H9N2 influenza virus. All operations
will be scaled up for application as a method in vaccine
production and this may be useful in the concentration of
other enveloped viruses.
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